Compare Abeona Therapeutics Inc (ABEO) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Roundhill NVDA WeeklyPay ETF trades at $36.14. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | NVDW | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $53.42 |
52-Week Low | $4.17 | $31.88 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NVDW trades at $34.32, down 0.38% on the day, with a bearish technical outlook indicated by moving averages and key indicators. The stock shows active dividend distributions, with multiple payouts in H1-26, but lacks available fundamental data such as P/E, revenue, or earnings metrics. No recent news or financial updates are accessible for deeper analysis.
The outlook is cautious due to the bearish technical signals and absence of current fundamental data. Investment opportunities hinge on future financial disclosures, while risks include potential underlying weaknesses and market volatility. Investors should await earnings reports for clarity on valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
